IPSEN BIOPHARMACEUTICALS CANADA
"IPSEN BIOPHARMACEUTICALS CANADA" is a word mark owned by Ipsen, S.A., filed at the CIPO on November 13, 2014. It is registered and covers classes 1, 5, 9, 10, 16, 38, 41, 42 and 44.
- Status
- Registered
- Since December 18, 2019
- Filed
- November 13, 2014
- Registered
- December 18, 2019
- Expires
- December 18, 2029
- Application no.
- 1702518
- Registration no.
- TMA1066761
- Office
- CIPO
- Canadian Intellectual Property Office
- Mark type
- Word mark
- 9 classes
Who owns IPSEN BIOPHARMACEUTICALS CANADA
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Ipsen, S.A.
France
Representative
Lavery, de Billy, LLP
Lavery, de Billy, LLP
What the mark covers
The products and services IPSEN BIOPHARMACEUTICALS CANADA is filed for, grouped by Nice class.
Chemicals for use in the manufacture of cosmetic, and chemicals for use in the manufacture of pharmaceutical preparations namely pharmaceutical preparations for use in oncology, pharmaceutical preparations for the treatment of endocrine diseases namely disorders of the thyroid namely thyroid cancer, thyroid nodules, primary hyperparathyroidism, hyperthyroidism, hypothyroidism, thyroiditis, parathyroid, adrenal and pituitary glands, acromegaly, diabetes, hypercosticism, hyperlipoproteinemia, hyperprolactinemia, hypoglycemia, pheochromocytoma, polyuropolydipsic syndrome, pharmaceutical preparations for the treatment of neurological diseases namely neurodegenerative diseases, neurosensory disorders, pain traumatisms, spinal cord injuries, neuromuscular disorders, convulsions, motor and sensory sequelae of cerebral origin, motor and sensory sequelae of medullary injury, cerebellar syndrome, muscle tone disorders and tremors, neurocognitive and neuropsychiatric sequelae, peripheral nervous system damage namely damage to upper and lower limbs, sensory, painful and trophic phenomena, sciatica and cervicobrachialgia, cranial nerve damage, damage linked to certain neurological syndromes namely post-concussion syndrome, epilepsy, parkinsonian syndromes, post-traumatic spinal syndrome, pharmaceutical preparations for the treatment of hematological disorders namely adenopathy, anemia, intravascular coagulation, sickle-cell anemia, monoclonal dysglobulinemia, leukemia, malignant non-Hodgkin's lymphomas, purpura, splenomegaly, hemorrhagic syndrome, mononucleosis syndromes, Hodgkin's disease, multiple myeloma, thalassemia, thrombopenia, polycythemia vera, pharmaceutical preparations for the treatment of gastroenterological diseases and disorders, and for the treatment of cardiovascular and cognitive disorders, pharmaceutical preparations for the treatment of urological diseases, pharmaceutical preparations for the treatment and prevention of neuromuscular disorders namely medicines nerviness, spasticity of the upper limbs, child spasticity, adult spasticity, focal spasticity, movement disorders, focal dystonia, cervical dystonia, pharmaceutical preparations for the treatment of muscular disorders namely muscular atrophy, muscular dystrophy, muscular dystonia, muscle spasms, neck strain, cramps, pharmaceutical preparations for the treatment of orthopedic disorders namely hip dislocation, spinal column deformation, curvature of the spine namely scoliosis, lordosis, cyphosis, pharmaceutical preparations for the treatment of disorders relating to age namely senile dementia, emphysema, Alzheimer's, and age-related macular degeneration, pharmaceutical preparations for the relief of pain, muscle spasm, hemifacial spasm and blepharospasm, pharmaceutical preparations for the treatment and prevention of cervical dystonia, torticollis, cerebral palsy, and spasticity, pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, namely dermatitis, eczema, skin lesions, hyperkeratosis, skin irritations, rosacea, psoriasis, acne, wound scars, pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and botulinum toxin derivatives used for the treatment of spasms and dystonias, cervical dystonia, focal dystonia, spasticity of the upper limbs, child spasticity, adult spasticity, focal spasticity, movement disorders, torticollis and cerebral pasly, muscle disorders and muscle spasms, hemifacial spasm and blepharospasm, chronic migraine, severe primary axillary hyperhidrosis, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin namely glabellar lines, wrinkles, and to prevent the development of wrinkles, pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and botulinum toxin derivatives for use in cosmetic surgery
Pharmaceutical preparations for use in oncology, pharmaceutical preparations for the treatment of endocrine diseases namely disorders of the thyroid namely thyroid cancer, thyroid nodules, primary hyperparathyroidism, hyperthyroidism, hypothyroidism, thyroiditis, parathyroid, adrenal and pituitary glands, acromegaly, diabetes, hypercosticism, hyperlipoproteinemia, hyperprolactinemia, hypoglycemia, pheochromocytoma, polyuropolydipsic syndrome, pharmaceutical preparations for the treatment of neurological diseases namely neurodegenerative diseases, neurosensory disorders, pain traumatisms, spinal cord injuries, neuromuscular disorders, convulsions, motor and sensory sequelae of cerebral origin, motor and sensory sequelae of medullary injury, cerebellar syndrome, muscle tone disorders and tremors, neurocognitive and neuropsychiatric sequelae, peripheral nervous system damage namely damage to upper and lower limbs, sensory, painful and trophic phenomena, sciatica and cervicobrachialgia, cranial nerve damage, damage linked to certain neurological syndromes namely post-concussion syndrome, epilepsy, parkinsonian syndromes, post-traumatic spinal syndrome, pharmaceutical preparations for the treatment of hematological disorders namely adenopathy, anemia, intravascular coagulation, sickle-cell anemia, monoclonal dysglobulinemia, leukemia, malignant non-Hodgkin's lymphomas, purpura, splenomegaly, hemorrhagic syndrome, mononucleosis syndromes, Hodgkin's disease, multiple myeloma, thalassemia, thrombopenia, polycythemia vera, pharmaceutical preparations for the treatment of gastroenterological diseases and disorders, and for the treatment of cardiovascular and cognitive disorders; pharmaceutical preparations for the treatment of urological diseases; pharmaceutical preparations for the treatment and prevention of neuromuscular disorders namely medicines nerviness, spasticity of the upper limbs, child spasticity, adult spasticity, focal spasticity, movement disorders, focal dystonia, cervical dystonia; pharmaceutical preparations for the treatment of muscular disorders namely muscular atrophy, muscular dystrophy, muscular dystonia, muscle spasms, neck strain, cramps; pharmaceutical preparations for the treatment of orthopedic disorders namely hip dislocation, spinal column deformation, curvature of the spine namely scoliosis, lordosis, cyphosis; pharmaceutical preparations for the treatment of disorders relating to age namely senile dementia, emphysema, Alzheimer's, and age-related macular degeneration; pharmaceutical preparations for the relief of pain, muscle spasm, hemifacial spasm and blepharospasm; pharmaceutical preparations for the treatment and prevention of cervical dystonia, torticollis, cerebral palsy, and spasticity; pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, namely dermatitis, eczema, skin lesions, hyperkeratosis, skin irritations, rosacea, psoriasis, acne, wound scars; pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and botulinum toxin derivatives used for the treatment of spasms and dystonias, cervical dystonia, focal dystonia, spasticity of the upper limbs, child spasticity, adult spasticity, focal spasticity, movement disorders, torticollis and cerebral pasly, muscle disorders and muscle spasms, hemifacial spasm and blepharospasm, chronic migraine, severe primary axillary hyperhidrosis, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin namely glabellar lines, wrinkles, and to prevent the development of wrinkles; pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and botulinum toxin derivatives for use in cosmetic surgery
Computer software for providing information and advertising in the fields of science, health, medicine, pharmacy and beauty
Medical apparatus and instruments, namely medical syringes, medical needles and introducers, needles for injection, needles for medical use, needles and needle free injunction systems, namely injection syringes
Printed matter, namely, pamphlets, books, brochures, newsletters, journals, magazines in the fields of science, health, medicine, pharmacy and beauty
Telecommunications services, namely, transmission of information, data namely text messages, images and sounds via computer terminals and the Internet namely electronic mail services
Training services in the fields of science, health, medicine and beauty; education services, namely, arranging and conducting colloquiums, conferences, conventions, seminars, symposiums in the fields of science, health, medicine, pharmacy and beauty
Scientific, medical and industrial research services and research and development services for new products in the fields of science, health, medicine, pharmacy and beauty; development services of chemical products, proprietary medicines, plants and pharmaceutical procedures in production of pharmacologically active substance and preparations, and of cosmetics; scientific and medical testing and diagnoses of chemical products, pharmaceutical products, cosmetic products, chemical, biological and bacteriological analysis; design and development of computers and software, all above mentioned services provided for others; information services, namely, providing advice and consultations in the field of scientific research
Medical services namely medical clinics, medical counselling namely medical house call services, medical diagnostic, testing services for medical purposes, medical clinics, medical diagnostic services, medical laboratory services, medical research services; providing hygienic and beauty care services for human beings, namely home care services, nursing home services, nursing care services, clinics and hospitals, beauty salons; information services, namely, providing information, advice and consulting services in the fields of scientific research and medicine namely providing medical and scientific research information in the field of pharmaceuticals, cosmetics and clinical trials
What has happened so far
Steps recorded by the CIPO, newest first.
- Owner Address Change / Changement d'adresse du propriétaire
- Amendment to Registration; Address/address
- Registered
- Registration Fee Notice Sent
- Registration Pending
- Advertised; Vol.66 Issue 3359
- Approved; APPROVED BY PROGRAM EX200M1
- Approval Notice Sent
- Rep for Service Name Changed
- Agent Name Changed
10 earlier steps on the official record.
About IPSEN BIOPHARMACEUTICALS CANADA
Who owns the trademark "IPSEN BIOPHARMACEUTICALS CANADA"?
The CIPO trademark "IPSEN BIOPHARMACEUTICALS CANADA" (application 1702518) is owned by Ipsen, S.A.
What is the status of "IPSEN BIOPHARMACEUTICALS CANADA"?
Its status at the CIPO is: registered.
When was "IPSEN BIOPHARMACEUTICALS CANADA" registered?
It was registered on December 18, 2019 and is due to expire on December 18, 2029.
Get this data via the API
Everything on this page comes from the Signa API. Pull IPSEN BIOPHARMACEUTICALS CANADA and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019deb3f-00a3-71e4-b50e-c3a141a4a287
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019deb3f-00a3-71e4-b50e-c3a141a4a287",
"object": "trademark",
"mark_text": "IPSEN BIOPHARMACEUTICALS CANADA",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "CA",
"application_number": "1702518",
"filing_date": "2014-11-13",
"nice_classes": [
1,
5,
9,
10,
16,
38,
41,
42,
44
],
"owners": [
{
"name": "IPSEN, S.A.",
"entity_id": "ent_019eb70f-0120-7551-b349-0ddd858e4183"
}
]
}